Abstract
HHLA2 is a newly identified B7 family member that modulates T-cell functions through interaction with TMIGD2 and possibly a second receptor, with coinhibition in two studies and costimulation in one study. HHLA2 is expressed on a variety of human cancers, and its coinhibitory function makes it a candidate for cancer immunotherapy. Clin Cancer Res; 21(10); 2201–3. ©2015 AACR. See related article by Janakiram et al., p. 2359

This publication has 10 references indexed in Scilit: